ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Clinical trials for ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for common lymphoma
Disease control OngoingThis study tests a combination of three drugs (acalabrutinib, lenalidomide, and rituximab) in 60 people with untreated stage III-IV follicular lymphoma. The goal is to see if the combo can shrink or eliminate tumors and keep the cancer under control. Participants must have measur…
Matched conditions: ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New cocktail therapy shows promise for lymphoma patients
Disease control OngoingThis early-phase study tests a combination of three drugs—rituximab, lenalidomide, and ibrutinib—in people with untreated follicular lymphoma, a slow-growing blood cancer. The main goal is to find the safest dose and understand side effects. About 33 participants with stage II to…
Matched conditions: ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug cocktail shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of three drugs—ALX148, rituximab, and lenalidomide—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to find the best dose and see how well the combo controls the cancer. About 47 adults w…
Matched conditions: ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 02, 2026 11:57 UTC